Global Pneumonia Vaccine Market Outlook 2020
According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.
According to our report, “Global Pneumonia Vaccine Market Outlook 2020”, the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government’s focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.
As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.
Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.
According to our report, “Global Pneumonia Vaccine Market Outlook 2020”, the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government’s focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.
As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.
Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. PNEUMOCOCCAL DISEASE AND VACCINE
4. GLOBAL PNEUMONIA VACCINE MARKET OUTLOOK 2020
4.1 Key Geographical Markets
5. REGULATORY OVERVIEW
5.1 United States
5.2 Europe
5.3 Rest of the World
5.3.1 India
5.3.2 China
5.3.3 Japan
6. COMPETITIVE ASSESSMENT
6.1 Market Share of Major Players
6.2 Company Profiles
6.2.1 GlaxoSmithKline
6.2.1.1 Business Overview
6.2.1.2 Key Financials
6.2.1.3 Strengths and Weaknesses
6.2.2 Pfizer
6.2.2.1 Business Overview
6.2.2.2 Key Financials
6.2.2.3 Strengths and Weaknesses
6.2.3 Merck
6.2.3.1 Business Overview
6.2.3.2 Key Financials
6.2.3.3 Strengths and Weaknesses
2. RESEARCH METHODOLOGY
3. PNEUMOCOCCAL DISEASE AND VACCINE
4. GLOBAL PNEUMONIA VACCINE MARKET OUTLOOK 2020
4.1 Key Geographical Markets
5. REGULATORY OVERVIEW
5.1 United States
5.2 Europe
5.3 Rest of the World
5.3.1 India
5.3.2 China
5.3.3 Japan
6. COMPETITIVE ASSESSMENT
6.1 Market Share of Major Players
6.2 Company Profiles
6.2.1 GlaxoSmithKline
6.2.1.1 Business Overview
6.2.1.2 Key Financials
6.2.1.3 Strengths and Weaknesses
6.2.2 Pfizer
6.2.2.1 Business Overview
6.2.2.2 Key Financials
6.2.2.3 Strengths and Weaknesses
6.2.3 Merck
6.2.3.1 Business Overview
6.2.3.2 Key Financials
6.2.3.3 Strengths and Weaknesses
LIST OF FIGURES:
Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in 5 Years of Age
Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014
Figure 6-4: GSK - Revenue by Business Segment (%), 2014
Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014
Figure 6-7: Pfizer - Revenue by Geography (%), 2014
Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014
Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014
Figure 6-10: Merck - Revenue by Business Segment (%), 2014
Figure 6-11: Merck - Revenue by Geography (%), 2014
Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014
Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in 5 Years of Age
Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014
Figure 6-4: GSK - Revenue by Business Segment (%), 2014
Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014
Figure 6-7: Pfizer - Revenue by Geography (%), 2014
Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014
Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014
Figure 6-10: Merck - Revenue by Business Segment (%), 2014
Figure 6-11: Merck - Revenue by Geography (%), 2014
Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014
LIST OF TABLES:
Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
Table 6-1: GSK - Pneumonia Vaccine Portfolio
Table 6-2: GSK - Key Financials (Million GBP), 2012-2014
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Pfizer - Pneumonia Vaccine Portfolio
Table 6-5: Pfizer - Key Financials (Million US$), 2012-2014
Table 6-6: Pfizer - Strengths and Weaknesses
Table 6-7: Merck - Pneumonia Vaccine Portfolio
Table 6-8: Merck - Key Financials (Millions US$), 2012-2014
Table 6-9: Merck - Strengths and Weaknesses
Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
Table 6-1: GSK - Pneumonia Vaccine Portfolio
Table 6-2: GSK - Key Financials (Million GBP), 2012-2014
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Pfizer - Pneumonia Vaccine Portfolio
Table 6-5: Pfizer - Key Financials (Million US$), 2012-2014
Table 6-6: Pfizer - Strengths and Weaknesses
Table 6-7: Merck - Pneumonia Vaccine Portfolio
Table 6-8: Merck - Key Financials (Millions US$), 2012-2014
Table 6-9: Merck - Strengths and Weaknesses
